ArticleJournal of neuro-oncology1995
Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?
Article in Journal of neuro-oncology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 106 citations in OpenAlex.
- Minimizing the risks of stereotactic brain biopsy in suspected central nervous system lymphoma: a retrospective database study.Journal of cancer research and clinical oncology · 2026Article
- Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature.Brain tumor pathology · 2024Review
- Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.Annals of hematology · 2023Article
- Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma.Neuro-oncology · 2022Article
- The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.Neuro-oncology · 2021Article
- Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.Journal of neuro-oncology · 2020Article
- Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.CNS oncology · 2019Article
- Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.Leukemia & lymphoma · 2019Article
- Non-Hodgkin Lymphoma With Longitudinally Extensive Transverse Myelopathy as the Initial Symptom: A Case Report.Frontiers in oncology · 2019Article
- 18F-FDG PET/CT in primary brain lymphoma.Journal of neuro-oncology · 2018Article
- Unusual relapse of primary central nervous system lymphoma.SpringerPlus · 2016Article
- A systematic approach to the diagnosis of suspected central nervous system lymphoma.JAMA neurology · 2013Review
- 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.BioMed research international · 2013Review
- Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England.Neuro-oncology · 2009Article
- The utility of body FDG PET in staging primary central nervous system lymphoma.Neuro-oncology · 2008Article
- Diagnosis and management of primary intraocular lymphoma: an update.Clinical ophthalmology (Auckland, N.Z.) · 2007Article
- Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.Journal of neuro-oncology · 2006Article
- Diagnosis and treatment of primary central nervous system lymphoma.Current oncology reports · 2005Review
- Primary central nervous system lymphoma.Current oncology reports · 2004Review
- Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.Medical oncology (Northwood, London, England) · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo demonstrate the extent of staging necessary to exclude occult systemic stage IV NHL before making a diagnosis of stage I AE PCNSL.
backgroundThe diagnosis of PCNSL requires the demonstration of malignant lymphocytes within the CNS (usually by biopsy) and finding no evidence of systemic NHL. Different staging approaches have been recommended, ranging from extensive systemic evaluation (including bone marrow examination) to a more focused approach (abdominal and pelvic CT) to no systemic evaluation. We have employed a staging regimen that included: ophthalmologic evaluation (including slit lamp examination); CT of chest, abdomen, and pelvis; bilateral iliac crest aspirate and biopsy; flow cytometry of circulating lymphocytes; and, in men, testicular ultrasound. DESIGN/
methodsWe carried out a retrospective review of 128 patients entered into the Mayo Lymphoma Project data bank (1975-1994).
resultsBetween the years 1975 and 1994, five patients (3.9%) were identified who fulfilled criteria for the diagnosis of PCNSL (typical clinical history, pathognomonic neuro-imaging, and histologic proof of NHL in brain tissue) but who had occult systemic NHL on staging (bone marrow 1, abdominal lymph nodes 3), or at autopsy (colon 1). Case histories are presented.
conclusionsPatients with apparent PCNSL may have systemic NHL. Complete staging is essential to the initial management of patients presenting as PCNSL to exclude systemic stage IV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.